Table 1 Baseline characteristics of the study population (n = 192)
Variables | All patients (n = 192) | CHA2DS2-VASc score ≥ 2 (n = 87) | CHA2DS2-VASc score 0-1 (n = 105) | p value |
|---|---|---|---|---|
Age, years | 60.43 ± 3.22 | 66.42 ± 11.4 | 55.47 ± 12.7 | < 0.001 |
BMI, kg/m2 | 25.96 ± 1.04 | 26.01 ± 1.43 | 25.92 ± 0.94 | 0.248 |
Hemoglobin, g/dL | 13.35 ± 0.56 | 13.27 ± 0.72 | 13.41 ± 0.63 | 0.173 |
White blood cell, 103/mm3 | 7.25 ± 2.76 | 6.13 ± 3.26 | 8.17 ± 2.07 | 0.002 |
Platelet count, × 103/μl | 278 ± 98 | 267 ± 78 | 303 ± 82 | 0.543 |
Creatinine, mg/dL | 0.96 ± 0.05 | 1.01 ± 0.03 | 0.91 ± 0.04 | 0.491 |
Total cholesterol, mg/dL | 188.52 ± 37.2 | 213.39 ± 45.7 | 167.92 ± 27.5 | 0.523 |
LDL-C, mg/dL | 102.07 ± 14.3 | 127.7 ± 12.8 | 82.5 ± 14.2 | 0.004 |
Triglycerides, mg/dL | 166.40 ± 31.2 | 168.5 ± 29.4 | 164.60 ± 36.2 | 0.372 |
Fasting glucose, mg/dL | 103.2 ± 48.3 | 118.4 ± 37.3 | 90.5 ± 39.2 | 0.062 |
C-Reactive protein (mg/dL) | 0.54 (0.26-0.87) | 0.83 (0.54-1.27) | 0.43 (0.26-0.87) | < 0.001 |
Serum albumin (g/dL) | 3.68 ± 0.43 | 3.59 ± 0.28 | 3.77 ± 0.39 | 0.423 |
HbA1c (%) | 6.2 ± 0.3 | 6.4 ± 0.8 | 6.1 ± 0.9 | 0.003 |
CHA2DS2-VASc (0-9) | 2.29 ± 1.46 | 4.92 ± 2.77 | 0.19 ± 0.08 | < 0.001 |
Endocan, ng/mL | 1.249 ± 0.298 | 1.776 ± 0.378 | 0.812 ± 0.314 | < 0.001 |
Men, n (%) | 98 (51.0) | 43 (49.4) | 55 (52.3) | 0.002 |
Hyperlipidemic, n (%) | 108 (56.3) | 52 (59.7) | 56 (53.3) | 0.075 |
Diabetes, n (%) | 133 (69.3) | 67 (77.0) | 66 (62.8) | < 0.001 |
Hypertension, n (%) | 118 (61.5) | 62 (71.2) | 56 (53.3) | 0.002 |
Smokers, n (%) | 132 (68.8) | 67 (77.0) | 65 (61.9) | 0.002 |
Hyperthyroidism, n (%) | 19 (10) | 9 (10.3) | 10 (9.5) | 0.873 |
Previous medications, n (%) | ||||
Aspirin | 82 (42.7) | 43 (49.4) | 39 (37.1) | 0.062 |
Other antiplatelet agents | 52 (27.0) | 26 (29.8) | 26 (24.7) | 0.192 |
ACEi/ARB | 65 (33.8) | 30 (34.4) | 35 (33.3) | 0.532 |
Beta-blocker | 45 (23.4) | 24 (27.5) | 21 (20) | 0.112 |
Calcium channel antagonist | 17 (8.8) | 9 (10.3) | 8 (7.6) | 0.142 |
Statin | 34 (15.6) | 18 (20.6) | 16 (15.2) | 0.213 |
Aldosterone antagonist | 51 (26.5) | 25 (28.7) | 26 (24.7) | 0.052 |
Verapamil/diltiazem | 18 (9.3) | 11 (12.6) | 7 (6.6) | 0.512 |
Diuretic | 6 (3.19) | 2 (2.2) | 4 (3.8) | 0.031 |
Antiarrhythmics (amiodarone, dronedarone, flecainide, propafenone, and sotalol) | 36 (18.7) | 23 (26.4) | 33 (31.4) | 0.091 |
VKA | 24 (12.5) | 13 (14.9) | 11 (10.4) | 0.152 |
NOAC | 58 (30.2) | 52 (59.7) | 6 (5.7) | < 0.001 |